Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (Chengdu WestVac)
重组变异新型冠状病毒疫苗（Sf9细胞）(成都威斯克)
Report date: 2025/07/08 20:00:08
Base Information
Drug NameRecombinant COVID-19 Variant Vaccine (Sf9 Cell) (Chengdu WestVac)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChengdu WestVac Biopharma Co Ltd
China Registration ClassN/A
Develop Information
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A